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Abstract Surveillance biopsies are increasingly used in the
post-transplant monitoring of pediatric renal allograft
recipients. The main justification for this procedure is to
diagnose early and presumably modifiable acute and
chronic renal allograft injury. Pediatric recipients are
theoretically at increased risk for subclinical renal allograft
injury due to their relatively large adult-sized kidneys and
their higher degree of immunological responsiveness. The
safety profile of this procedure has been well investigated.
Patient morbidity is low, with macroscopic hematuria being
the most common adverse event. No patient deaths have
been attributed to this procedure. Longitudinal surveillance
biopsy studies have revealed a substantial burden of
subclinical immunological and non-immunological injury,
including acute cellular rejection, interstitial fibrosis and
tubular atrophy, microvascular lesions and transplant
glomerulopathy. The main impediment to the implementa-
tion of surveillance biopsies as the standard of care is the
lack of demonstrable benefit of early histological detection
on long-term outcome. The considerable debate surround-
ing this issue highlights the need for multicenter, prospec-
tive, and randomized studies.
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Protocol renal allograft biopsies
Introduction
The surveillance biopsy, also known as the ‘protocol biopsy,’
isdefinedasthesamplingofrenaltissueinpatientswithstable
allograft function at predetermined time points [1, 2],
typically between 1-12-months post-transplantation. Surveil-
lance biopsies are increasingly used to diagnose subtle (i.e.,
subclinical) acute and chronic pathology in renal allografts.
In some centers, they are also performed to evaluate baseline
histology at implantation (i.e., ‘donor’ or ‘implantation’
biopsies) or to determine the efficacy of acute rejection (AR)
therapy (i.e., ‘follow-up’ biopsies) [3]. The main justification
for this procedure is to detect early and presumably
modifiable renal allograft injury. However, in the pediatric
renal transplant community, considerable debate about the
clinical utility of this invasive procedure remains, particularly
in the low immunological risk recipient [2, 4–10]. Similarly,
in the absence of obvious graft dysfunction at predetermined
time points, private insurers may be reluctant to provide
coverage for this procedure.
Rationale for surveillance biopsies in pediatric renal
transplant recipients
Several unique factors merit a higher index of suspicion for
subclinical renal allograft injury in pediatric recipients. The
first is the large mass of the adult-sized kidney (ASK)
relative to the small pediatric recipient [11]. In one study in
the pre-surveillance biopsy era, less than 50% of young
pediatric recipients with acute rejection on biopsy actually
manifested an appreciable increase in their baseline sCr
values [12]. In the original Winnipeg pediatric cohort, AR,
diagnosed on surveillance biopsy but without functional
deterioration (i.e., subclinical acute rejection, SCR), was
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managed on antibody, steroids, tacrolimus, and mycophe-
nolate mofetil [13]. In this cohort, neither the estimated
GFR (eGFR), nor the presence of proteinuria was predictive
of interstitial fibrosis and tubular atrophy (IF/TA) [13],
formerly known as ‘CAN’ [14].
Pediatric renal transplant recipients also exhibit a high
degree of immunological responsiveness. Young peritoneal
dialysis patients manifest higher total lymphocyte counts,
CD4/CD8 ratios and increased blastogenesis when compared
to their older counterparts [15]. Similarly, following sensitiz-
ing events such as blood transfusions, pediatric patients are
five times more likely to develop anti-HLA antibodies than
older patients [16]. Thus, it has been postulated that the large
renal mass of an ASK may conceal incipient acute and
chronic renal allograft injury in the pediatric recipient [3, 10,
13]. Since children have more robust immunological
responses, they are potentially at higher risk for SCR [10, 13].
Biopsy procedure
The surveillance biopsy is typically performed under
conscious sedation in an outpatient unit [17]. Depending
on center expertise, the procedure is performed by a
pediatric nephrologist or an interventional radiologist.
Conscious sedation (e.g., intravenous midazolam or propo-
fol) is administered by an anesthesiologist or an intensivist.
Specimen adequacy is determined by a histopathology
technician who is also present during the procedure.
A renal pole situated away from the main transplant
vessels is localized with ultrasound in real-time. Ideally,
two tissue cores are obtained using an 18-gauge or a 16-
gauge disposable needle [17]. While the utilization of a
larger diameter needle improves specimen adequacy (at
least seven glomeruli and two arteries) [18], its use is
associated with a higher incidence of post-biopsy hemor-
rhage [17, 19]. Patients are recovered for a minimum of 4 h,
as the majority of biopsy-related complications manifest
within the first 4 h of biopsy [17].
Renal tissue specimens are fixed in formalin and
embedded in paraffin. For Banff scoring, paraffin sections
are processed with hematoxylin and eosin (H&E), periodic
acid Schiff (PAS), periodic acid methenamine Schiff
(PAMS) and Masson’s trichrome (MT) stains [18]. To
facilitate the diagnosis of antibody-mediated rejection
(AMR), most centers also perform C4d staining on frozen
tissue. When the protocol biopsy is used for research
purposes, upon procurement, a portion of the core (e.g., 1/3
or 1/2) is snap-frozen in liquid nitrogen and stored at −80°C
for future analyses [19].
Adverse events related to surveillance biopsies
The safety profile of surveillance biopsies has been docu-
mented in more than 1,900 adult and 250 pediatric recipients
who underwent approximately 5,000 and 700 biopsy proce-
dures, respectively (Table 1). Importantly, the incidence of
major adverse events such as allograft loss is extremely low
and no deaths have been reported in these series [17, 20–25].
Macroscopic hematuria was the most-commonly reported
adverse event. Its frequency increased with the use of a larger
diameter needle (16-gauge vs. 18-gauge) [17, 20] and the
penetration of renal medulla or highly inflamed arteries [21].
It should be noted that since many centers do not routinely
perform post-biopsy ultrasound, the incidence of perinephric
hematomas and arteriovenous fistulae is likely to be under-
reported. In all of these series, major (i.e., highly invasive)
post-biopsy interventions were rare [17, 20–25]( T a b l e2).
Surveillance biopsies for the detection of subclinical
acute cellular rejection
Definition of subclinical acute cellular rejection
Rush et al. [26] originally described the condition,
“subclinical rejection” (SCR), in which one-third of adult
renal transplant recipients managed on steroids, cyclospor-
Incidence (%)
Adverse event Adult kidney transplant recipients Pediatric kidney transplant recipients
Macroscopic hematuria 2.8-3.1 2.7-8.8
Perinephric hematoma* 3.3 13.4
Arteriovenous fistula* 9.0 1.3
Bowel perforation 0.04 0
Vasovagal reaction 0.8 0
Allograft loss 0.04-0.3 0
Death 0 0
Table 1 Incidence of adverse
events following surveillance
biopsies in adult and pediatric
kidney transplant recipients
[17, 20–25]
*May be under-reported
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surveillance biopsy. Notably absent was a concomitant
increase in their baseline serum creatinine (sCr) values.
These findings led to the implementation of biopsies 1, 2, 3,
6, and 12 months post-transplantation as standard of care
for renal allograft monitoring [27].
In the last decade, the definition of SCR has been
subclassified to include: (1) Acute subclinical rejection
(A-SCR), in which the degree of cellular interstitial and
tubular infiltration reach Banff criteria for AR (≥ i2t2,
respectively) (Figs. 1a and 2). Borderline subclinical
rejection (B-SCR), characterized by milder degrees of
inflammation (i0-1 and/or t1-t3) [2, 28] (Fig. 1b). However,
as the differences in cellular infiltration (e.g., activated
macrophages) and pro-inflammatory gene expression (e.g.,
tumor necrosis factor alpha, interleukin (IL)-1 beta, trans-
forming growth factor beta, interferon gamma, IL-2, IL-4,
IL-10, and IL-15, granzyme B, perforin, Fas ligand, and
CD152 costimulation molecule) are quantitative rather than
qualitative, it is likely that A-SCR and B-SCR merely
represent different potencies of the same acute inflamma-
tory process [19, 29, 30].
Epidemiology of subclinical acute cellular rejection
The incidence of all forms of SCR is influenced by both the
amount and potency of immunosuppression [2, 28]. In the
cyclosporine/azathioprine era, SCR was detected in approx-
imately 30% adult recipients during the first 3 months post-
transplant [26, 27]. Similarly, in the landmark Australian
report of adult kidney-pancreas recipients undergoing
1,000 surveillance biopsies over 10 years, the incidence
of SCR was 46% at 3 months post-transplant. By 1 year
post-transplant, the incidence had decreased to 18% [2],
possibly due to the phenomenon of accommodation. The
use of more potent immunosuppressive medications such
as antibody induction, tacrolimus, and mycophenolate
m o f e t i lh a sl e dt oam a r k e dr e d u c t i o ni nt h eo v e r a l l
prevalence of SCR (3-5% for A-SCR and 11% for B-SCR)
[31, 32]. The paucity of acute inflammation reported in
these recent studies have led some investigators to
question the value of the surveillance biopsy in the low
immunological risk adult recipient [31, 32].
In contrast, in children, the incidence and prevalence of
SCR remains high. In a recent report of pediatric recipients
managed on basiliximab induction, steroids, tacrolimus or
sirolimus and mycophenolate mofetil, 29% patients had
either A-SCR or B-SCR at 3 months post-transplant [33].
However, in this study, the dosage of mycophenolate
mofetil (600–900 mg/m
2/day) was lower than a recent task
force dosage recommendation of 1,200 mg/m
2/day [34].
Incidence (%)
Intervention Adult kidney transplant recipients Pediatric kidney transplant recipients
Blood transfusion 0.1-0.7 0
Bladder catheterization 0.3-0.6 2.3
Radiological procedures 0.04 2.3
Surgical procedures 0.09-0.4 0
Prolonged hospitalization 2.0% 3.5%
Table 2 Post-biopsy interven-
tions in adult and pediatric
kidney transplant recipients
[17, 20–25]
Fig. 1 a Surveillance renal allograft biopsy showing acute cellular
subclinical rejection (A-SCR) with tubulitis (t2), PAS stain. b
Surveillance renal allograft biopsy showing borderline cellular
subclinical rejection (B-SCR) with minimal interstitial infiltrates (i1)
and mild tubulitis (t1), PAS stain
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particular study may reflect under-immunosuppression.
In the Winnipeg cohort (in which patients receive
induction, steroids, tacrolimus, or sirolimus and mycophe-
nolate mofetil 1,200 mg/m
2/day), by 7–12 months post-
transplant, the incidence of A-SCR had declined to 8%,
with an additional 13% ‘spike’ occurring in nonadherent
adolescents after 3 years post-transplantation. Borderline
SCR was observed in up to 20% of surveillance biopsies,
with a peak incidence occurring at 7–12 months post-
transplant [35]. In another pediatric report, A-SCR was
seen in the late post-transplant period (19% at 3 years and
16% at 4 years post-transplant) [36].
Pathogenicity of subclinical acute cellular rejection
The potential for SCR to cause significant renal allograft
injury continues to be debated. In both adult and pediatric
recipients, A-SCR and B-SCR have been associated with the
development and progression of IF/TA [13, 27, 35–41],
impaired glomerular adaptation [42], late allograft dysfunc-
tion [36–38] and decreased allograft survival [39, 43–46].
Given these findings, it is not unreasonable to assume that
the immunosuppressive treatment of SCR would improve
renal allograft outcomes. However, studies in adult recipients
are collectively equivocal. In some reports, steroid treatment
of SCR resulted in lower IF/TA scores at 6 months and
2 years post-transplant [40, 41, 47]; and fewer subsequent
AR episodes and lower sCr values at 2 years post-transplant
[47]. Other studies, however, showed no significant differ-
ences in chronic histology or in renal allograft function and
survival [32, 48, 49]. These conflicting results reflect, in part,
variable definitions of SCR and a lack of recognition of
antibody-mediated rejection (AMR). To date, no pediatric
studies have evaluated the immunosuppressive treatment of
SCR using a randomized and prospective study design.
In one pediatric retrospective study, increasing the dosage
of mycophenolate mofetil by 50% resulted in a significantly
reduced prevalence of SCR from 44–29% [33]. However,
this reduction was accompanied by a marked increase in
polyoma (BK) viremia from 3–30%. Thus, in the manage-
ment of SCR, the risk of pathogenicity must be weighed
against the risk of over-immunosuppression, which includes
opportunistic infections, and possibly, post-transplant lym-
phoproliferative disease.
Surveillance biopsies for the detection of chronic renal
allograft injury
Patterns of chronic renal allograft injury
Longitudinal observational surveillance studies demonstrate
that chronic renal allograft injury develops early after
transplantation [35, 37], with 89% patients manifesting grade
1 or higher IF/TA by 7–12 months [35]. Both adult and
pediatric surveillance biopsy studies reveal a biphasic pattern
of pathological changes [35, 37]. Chronic tubulointerstitial
injury develops within the first 12 months post-transplant,
followed by chronic microvascular injury (vascular fibrous
intimal thickening, arteriolar hyalinosis and glomeruloscle-
rosis) at 2 years post-transplant and beyond [35, 37, 50–52].
Risk factors for chronic renal allograft injury
In children, multivariate analyses provide insights into the
etiology of chronic renal allograft lesions. Interstitial fibrosis/
tubular atrophy and arteriolar hyalinosis are associated with
low recipient BSA, which is a surrogate for the renal
hypoperfusion resulting from the transplantation of ASK’s
into small recipients [35, 50]. The development of glomer-
ulosclerosis lesions parallels the onset of vascular lesions,
implicating CNI-mediated ischemia as a contributing factor
Fig. 2 a Surveillance renal allograft biopsy showing subclinical AMR
with diffuse C4d+staining of peritubular capillaries and b Peritubular
capillaritis (ptc2)
756 Pediatr Nephrol (2012) 27:753–760[35, 51, 52]. Other potentially modifiable risk factors include
AR and all types of SCR (IF/TA), donor hypertension
(vascular fibrous intimal thickening) and post-transplant
obesity (IF/TA) [35].
Surveillance biopsies for the detection
of antibody-mediated rejection
Antibody-mediated rejection is characterized by the variable
presence of: 1. Acute tissue injury, such as glomerulitis and
peritubular capillaritis (ptc); 2. Complement degradation
product (C4d) staining; and 3. Circulating donor-specific
antibody (DSA) [53]. In a primate alloantibody model, the
progression of AMR to renal allograft failure begins with the
formation of DSA (most commonly anti-HLA Class II
antibodies), followed by complement activation and C4d
deposition in glomeruli and ptc. The sequelae of persistent
glomerular inflammation is basement membrane duplication,
mesangial matrix expansion and mesangial cell interposition, a
condition known as transplant glomerulopathy (TG) [54, 55].
In adult recipients, AMR is more deleterious than acute
cellular rejection (35% renal allograft survival, compared to
100% renal allograft survival, respectively, at 4 years post-
transplant) [56]. Similarly, in pediatric recipients, C4d-
positive ptc is associated with a higher prevalence of TG
and late renal allograft loss [57]. Subclinical acute AMR is
increasingly recognized on surveillance biopsy (Figs. 2a and
b), but its precise incidence is currently unknown. However,
subclinical TG is well described in adult recipients, with a
cumulative incidence of 3% (1 year), 6% (2 years), 9%
(3 years) and 12% (5 years) [55]. By 1 year post-transplant,
TG was already associated with reduced eGFR and increased
proteinuria [55]. In the Winnipeg pediatric cohort, the overall
prevalence of TG was 22% in patients with a mean follow-
up of 44±5 months. Among these, 44% were C4d-positive
on surveillance biopsy and 22% had DSA [35].
Limitations of surveillance biopsy findings
A typical biopsy core represents only 0.04% of the renal
allograft [4]. Sampling error has been estimated to affect up
to 25% of surveillance biopsies [58], leading to erroneous
diagnoses. Noninvasive technologies (e.g., microarrays,
proteonomics, and NMR spectroscopy) utilizing blood or
urine can potentially obviate sampling error, but must be
validated in large and heterogeneous populations. Thus, the
surveillance biopsy, while flawed, remains the gold stan-
dard for the diagnosis of renal allograft pathology.
Surveillance biopsy data are also susceptible to the ‘era
effect.’ The largest and most frequently cited surveillance
biopsy study describing the natural history study of ‘CAN’ in
kidney-pancreas recipients was performed before the routine
use ofC4d stainingand solid-phase assaysfor DSA detection.
In light of the subsequent observation of the negative impact
of antibody-mediated injury on renal allograft survival, it is
likely that some proportion of the IF/TA reported in this study
actuallyresultedfromAMR[59]. In adult recipients managed
in the tacrolimus/sirolimus era, there is a growing body of
evidence showing that mild IF/TA is minimally progressive
[60] and in the absence of acute inflammation, it is not
associated with renal allograft dysfunction or diminished
graft survival [61].
Conclusions
Pediatric recipients are theoretically at increased risk for
subclinical renal allograft injury due to their relatively large
adult-sized kidneys and their higher degree of immunological
responsiveness. In these patients, longitudinal surveillance
biopsy studies have revealed a substantial burden of subclin-
ical immunological and non-immunological injury, including
acutecellularrejection,interstitialfibrosisandtubularatrophy,
microvascular lesions and transplant glomerulopathy. The
main impediment to the implementation of surveillance
biopsies as standard of care is the lack of demonstrable
benefit of early histological detection on long-term outcome.
The considerable debate surrounding this issue speaks to the
need for multicenter, prospective and randomized studies,
which are currently lacking. In the absence of a direct benefit
of longitudinal screening, the most pragmatic use of the
surveillance biopsy is in guiding the post-transplant manage-
ment of the higher immunological risk pediatric recipient.
Questions (answers are provided after references)
1) The following statements about subclinical acute
cellular rejection (SCR) are true except:
a) The incidence of SCR is dependent on the amount
and potency of immunosuppression
b) In adult renal transplant recipients, the incidence of
SCR is decreasing
c) In pediatric renal transplant recipients, the inci-
dence of SCR is decreasing
d) SCR is defined as Banff histology showing acute
rejection in patients with stable allograft function
2) True or False: Acute subclinical rejection (A-SCR) is
defined as acute rejection by Banff criteria (≥i2t2) with
a concomitant increase in the serum creatinine.
3) True or False: Borderline subclinical rejection (B-
SCR) is defined as acute rejection which does not meet
Banff criteria (i0-i1 and/or t1-t3) without a concomitant
increase in the serum creatinine.
Pediatr Nephrol (2012) 27:753–760 7574) The following are complications of surveillance biop-
sies except:
a) Macroscopic hematuria
b) Arteriovenous fistula
c) Death
d) Bowel perforation
5) All of the following increase the risk of post-biopsy
hemorrhage except:
a) Acute rejection with vascular involvement
b) Adult-sized kidney (ASK)
c) Penetration of the renal medulla
d) Use of a 16-gauge needle
6) Which of the following lesions have been observed in
surveillance biopsies?
a) Acute cellular rejection
b) Interstitial fibrosis and tubular atrophy (IF/TA)
c) Transplant glomerulopathy (TG)
d) All of the above
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